Biographical Sketch

A. Personal Statement Dr. Khatri is an Assistant Professor at the Institute for Immunity, Transplantation, and Infection and the Center for Biomedical Informatics Research, Department of Medicine at Stanford University. Dr. Khatri has more than 15 years of professional experience in the areas of bioinformatics, computational biology, and translational medicine. He actively collaborates with many investigators on the Stanford campus, and at other institutes, with a goal to disseminate and implemented newly-invented diagnostic markers and therapeutic targets. He develops methods for the integration and analysis of high throughput genomics and proteomics data. He is well known for work on the development of ontological and pathway analysis of high throughput molecular data, and leveraging publicly available data for integrated, multi-cohort analyses for identification of diagnostic and therapeutic biomarkers. Dr. Khatri developed the first tool, Onto-Express, for analysis of microarray data using Gene Ontology. He expanded his work in ontological analysis to develop a suite of web-based open access tools, Onto-Tools. Currently, more than 15,000 people around the world are registered as Onto-Tools users. His recent work is focused on developing computational methods for integrated, multi-cohort analysis of publically available data to increase the sample size as well as better account for heterogeneity observed in real world patient population. Using these methods, he has integrated data sets from multiple centers consisting of distinct patient cohorts with different biological and technical confounders (i) to identify highly specific and sensitive biomarkers for acute rejection across all transplanted organs, cancers (pancreatic cancer, small cell and non-small cell lung cancer), and infectious diseases (sepsis, respiratory viral infections, tuberculosis) (ii) to suggest repositioning of FDA-approved drugs for treating transplant patients, and (iii) to identify novel gene involved in non small cell lung cancer and pancreatic cancer carcinogenesis that may be a potential drug target.